Barings LLC Acquires Shares of 8,100 Qiagen N.V. (QGEN)

Barings LLC acquired a new stake in Qiagen N.V. (NASDAQ:QGEN) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 8,100 shares of the company’s stock, valued at approximately $255,000.

Several other institutional investors have also made changes to their positions in QGEN. Acrospire Investment Management LLC lifted its position in shares of Qiagen by 11.7% in the second quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock valued at $112,000 after acquiring an additional 349 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its position in shares of Qiagen by 0.5% in the second quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock valued at $133,000 after acquiring an additional 20 shares in the last quarter. Quadrant Capital Group LLC lifted its position in shares of Qiagen by 4.1% in the second quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock valued at $183,000 after acquiring an additional 225 shares in the last quarter. Koch Industries Inc. purchased a new position in shares of Qiagen in the second quarter valued at about $231,000. Finally, Trexquant Investment LP purchased a new position in shares of Qiagen in the third quarter valued at about $234,000. Institutional investors and hedge funds own 62.37% of the company’s stock.

Shares of Qiagen N.V. (NASDAQ:QGEN) opened at $30.84 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.33 and a quick ratio of 4.78. Qiagen N.V. has a 52-week low of $27.51 and a 52-week high of $36.34. The company has a market capitalization of $7,062.02, a PE ratio of 25.22, a P/E/G ratio of 1.90 and a beta of 1.10.

Qiagen (NASDAQ:QGEN) last issued its quarterly earnings data on Monday, November 6th. The company reported $0.32 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.32. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. The company had revenue of $364.00 million for the quarter, compared to analysts’ expectations of $363.42 million. During the same period in the previous year, the firm posted $0.29 earnings per share. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. analysts anticipate that Qiagen N.V. will post 1.25 EPS for the current fiscal year.

QGEN has been the topic of several research analyst reports. Cowen restated a “hold” rating and issued a $33.00 price objective on shares of Qiagen in a research report on Monday, August 14th. Commerzbank reiterated a “buy” rating on shares of Qiagen in a research report on Thursday, August 17th. DZ Bank reiterated a “neutral” rating on shares of Qiagen in a research report on Monday, August 28th. Zacks Investment Research upgraded Qiagen from a “hold” rating to a “buy” rating and set a $39.00 target price on the stock in a research report on Tuesday, October 10th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of Qiagen in a research report on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company’s stock. Qiagen presently has an average rating of “Hold” and an average price target of $34.06.

WARNING: “Barings LLC Acquires Shares of 8,100 Qiagen N.V. (QGEN)” was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/07/barings-llc-acquires-shares-of-8100-qiagen-n-v-qgen.html.

About Qiagen

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Institutional Ownership by Quarter for Qiagen (NASDAQ:QGEN)

What are top analysts saying about Qiagen N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Qiagen N.V. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit